PMID: 3754998Mar 1, 1986Paper

Behavior of the biological aging index and serum lipids in treatment with X50

ZfA. Zeitschrift Für Alternsforschung
W ReuterW Herrmann

Abstract

Lipid metabolic disorders are clinical relevant for the middle and old age. The presented paper shows that decreased HDL-cholesterol and increased triglycerides enlarge the value of pre-ageing. Therefore is a lipid lowering treatment a special problem of gerontology. We have treated 15 patients (age 56.7 +/- 7.8 years) with hypercholesterolemia and hypertriglyceridemia with the new developed lipids regulans X50 = 1-benzyl-3-(1-carboxy-1-methylethoxy)-4-methylpyrazol. There was a significant decreases of serumtriglycerides (47%) in all patients. Half of the patients showed a significant decreases of total cholesterol (32%). Biological age index and biological age were not influenced. To demonstrate an influence of biological age there are needed longterm treatments in patients with lipid metabolic disorders.

Related Concepts

Related Feeds

Cell Aging (Keystone)

This feed focuses on cellular aging with emphasis on the mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.